

Eligible patients new to ROLVEDON™ can receive their first-cycle dose free of charge.

### Patient Eligibility Criteria

- Patient must be new to ROLVEDON™
- Patient must be a US resident with a legal US mailing address
- Patient's diagnosis is consistent with the FDA-approved indication for ROLVEDON
- Limited to ONE dose per patient
- ROLVEDON is administered in the outpatient setting
- Patient is enrolled in Access4Me™ Patient Support Program

### How it works

#### Product Replacement

*Designed so providers can utilize product on hand without waiting for patient-specific shipments*

- Select "First-Cycle Patient Support" when enrolling the patient in Access4Me Program
- Enrollment form must be received and approved prior to the date of injection
- Access4Me will conduct a benefits investigation, communicate the results to the office, and confirm eligibility for the patient's free dose
- Once the patient is approved, providers utilize ROLVEDON from their existing supply and submit for a free replacement unit (additional form required). No claim for ROLVEDON can be submitted to any insurer, payer or third-party.
- Replacement product is shipped directly to the facility address where the product was administered
- Product Replacement requests need to be submitted by end of month after treatment.

### Complete Terms and Conditions

To utilize the Product Replacement option, patients must be enrolled in Access4Me and patient consent is required. ROLVEDON received under the First-Cycle Patient Support program is provided at no charge for the benefit of the patient only. Neither the patient nor the provider, nor anyone acting on behalf of the patient or provider, may seek reimbursement for the value of ROLVEDON received from this program from any insurer, payer, or third-party, including any federal health care program, any flexible spending accounts or healthcare savings accounts. Not valid for ROLVEDON administered in the inpatient setting.

The program covers product only and does not cover any health care provider charges related to the administration of the product or other treatment costs. Participation in the First-Cycle Patient Support program does not impose any future obligation on the patient or provider to use, purchase, order, or prescribe ROLVEDON or any other Spectrum product or service. This First-Cycle Patient Support program is limited to a single dose of ROLVEDON per patient per lifetime. Spectrum Pharmaceuticals reserves the right to modify or terminate the program without notice at any time. This is not health insurance.

### Program Limitations

**Maximum utilization limits as described below apply to all ROLVEDON product received via product replacement. Program will be available for a limited time.**

#### Utilization Limits

- **Health Care Providers**—Individual providers are limited to a maximum of 20 ROLVEDON units within a rolling 3-month period
- **Sites of Care**—Any single pharmacy or site of care is limited to a maximum of 70 ROLVEDON units within a rolling 3-month period

